The use of agonistic anti-CD40 therapy in treatments for cancer
Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for c...
| Main Authors: | , , , , |
|---|---|
| Format: | Journal Article |
| Published: |
Taylor & Francis
2012
|
| Subjects: | |
| Online Access: | http://informahealthcare.com/loi/iri http://hdl.handle.net/20.500.11937/49580 |
| Summary: | Agonistic anti-CD40 antibody is a potent stimulator of anti-tumor immune responses due to itsaction on both immuneand tumor cells. It has the ability to “precondition” dendritic cells, allowingthem to prime effective cytotoxic T-cell responses. Thus, anti-CD40 antibody provides an idealtherapy for combination with traditional cancer treatments (i.e., chemotherapy, surgery) in orderto elicit immune-mediated anti-tumor effects. This review summarizes the mechanisms of actionof agonistic anti-CD40, the use of mouse models to investigate its effects and combinations withother therapies in vivo, and current clinical trials combining humanized anti-CD40 antibody withchemotherapy and/or other immunotherapies. |
|---|